Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Melamed, E' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 114 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Lev, N; Maimon, S; Rappaport, ZH; Melamed, E
      Spinal dural arteriovenous fistulae - A diagnostic challenge

      ISRAEL MEDICAL ASSOCIATION JOURNAL
    2. Wangberg, I; Munthe, J; Pirrone, N; Iverfeldt, A; Bahlman, E; Costa, P; Ebinghaus, R; Feng, X; Ferrara, R; Gardfeldt, K; Kock, H; Lanzillotta, E; Mamane, Y; Mas, F; Melamed, E; Osnat, Y; Prestbo, E; Sommar, J; Schmolke, S; Spain, G; Sprovieri, F; Tuncel, G
      Atmospheric mercury distribution in Northern Europe and in the Mediterranean region

      ATMOSPHERIC ENVIRONMENT
    3. Albanese, A; Bonuccelli, U; Brefel, C; Chaudhuri, KR; Colosimo, C; Eichhorn, T; Melamed, E; Pollak, P; Van Laar, T; Zappia, M
      Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease

      MOVEMENT DISORDERS
    4. Djaldetti, R; Melamed, E; Gadoth, N
      Abnormal skin wrinkling in the less affected side in hemiparkinsonism - a possible test for sympathetic dysfunction in Parkinson's disease

      BIOMEDICINE & PHARMACOTHERAPY
    5. Djaldetti, R; Rosmarin, V; Ziv, I; Melamed, E
      The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    6. Offen, D; Panet, H; Galili-Mosberg, R; Melamed, E
      Catechol-O-methyltransferase decreases levodopa toxicity in vitro

      CLINICAL NEUROPHARMACOLOGY
    7. Djaldetti, R; Melamed, E
      New therapies for Parkinson's disease

      JOURNAL OF NEUROLOGY
    8. Barzilai, A; Melamed, E; Shirvan, A
      Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?

      CELLULAR AND MOLECULAR NEUROBIOLOGY
    9. Gilgun-Sherki, Y; Melamed, E; Offen, D
      Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier

      NEUROPHARMACOLOGY
    10. Panet, H; Barzilai, A; Daily, D; Melamed, E; Offen, D
      Activation of nuclear transcription factor kappa B (NF-kappa B) is essential for dopamine-induced apoptosis in PC12 cells

      JOURNAL OF NEUROCHEMISTRY
    11. Daily, D; Vlamis-Gardikas, A; Offen, D; Mittelman, L; Melamed, E; Holmgren, A; Barzilai, A
      Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the Ras-phosphoinositide 3-kinase and jun N-terminal kinase pathways

      JOURNAL OF BIOLOGICAL CHEMISTRY
    12. Daily, D; Vlamis-Gardikas, A; Offen, D; Mittelman, L; Melamed, E; Holmgren, A; Barzilai, A
      Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by activating NF-kappa B via Ref-1

      JOURNAL OF BIOLOGICAL CHEMISTRY
    13. Ziv, I; Shirvan, A; Offen, D; Barzilai, A; Melamed, E
      Molecular biology of dopamine-induced apoptosis - Possible implications for Parkinson's disease

      PARKINSON'S DISEASE
    14. Giladi, N; Melamed, E
      The role of functional neurosurgery in Parkinson's disease

      ISRAEL MEDICAL ASSOCIATION JOURNAL
    15. Offen, D; Kaye, JF; Bernard, O; Merims, D; Coire, CI; Panet, H; Melamed, E; Ben-Nun, A
      Mice overexpressing bcl-2 in their neurons are resistant to myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE)

      JOURNAL OF MOLECULAR NEUROSCIENCE
    16. Merims, D; Galili-Mosberg, R; Melamed, E
      Is there addiction to levodopa in patients with Parkinson's disease?

      MOVEMENT DISORDERS
    17. Rudnick, A; Ezra, Y; Melamed, E
      Breaking bad news and personality assessment

      PATIENT EDUCATION AND COUNSELING
    18. Rabey, JM; Sagi, I; Huberman, M; Melamed, E; Korczyn, A; Giladi, N; Inzelberg, R; Djaldetti, R; Klein, C; Berecz, G
      Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa

      CLINICAL NEUROPHARMACOLOGY
    19. Melamed, E; Offen, D; Shirvan, A; Ziv, I
      Levodopa - an exotoxin or a therapeutic drug?

      JOURNAL OF NEUROLOGY
    20. Offen, D; Elkon, H; Melamed, E
      Apoptosis as a general cell death pathway in neurodegenerative diseases

      JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT
    21. Galili-Mosberg, R; Gil-Ad, I; Weizman, A; Melamed, E; Offen, D
      Haloperidol - induced neurotoxicity - possible implications for tardive dyskinesia

      JOURNAL OF NEURAL TRANSMISSION
    22. Shirvan, A; Shina, R; Ziv, I; Melamed, E; Barzilai, A
      Induction of neuronal apoptosis by Semaphorin3A-derived peptide

      MOLECULAR BRAIN RESEARCH
    23. Hochman, A; Liang, HY; Offen, D; Melamed, E; Sternin, H
      Developmental changes it antioxidant enzymes and oxidative damage in kidneys, liver and brain of bcl-2 knockout mice

      CELLULAR AND MOLECULAR BIOLOGY
    24. Zilkha-Falb, R; Barzilai, A; Djaldeti, R; Ziv, I; Melamed, E; Shirvan, A
      Involvement of T-complex protein-1 delta in dopamine triggered apoptosis in chick embryo sympathetic neurons

      JOURNAL OF BIOLOGICAL CHEMISTRY
    25. Offen, D; Sherki, Y; Melamed, E; Fridkin, M; Brenneman, DE; Gozes, I
      Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease

      BRAIN RESEARCH
    26. Agid, Y; Ahlskog, E; Albanese, A; Calne, D; Chase, T; De Yebenes, J; Factor, S; Fahn, S; Gershanik, O; Goetz, C; Koller, W; Kurth, M; Lang, A; Lees, A; Lewitt, P; Marsden, D; Melamed, E; Michel, PP; Mizuno, Y; Obeso, J; Oertel, W; Olanow, W; Poewe, W; Pollak, P; Przedzorski, S; Quinn, N; Raisman-Vozari, R; Rajput, A; Stocchi, F; Tolosa, E
      Levodopa in the treatment of Parkinson's disease: A consensus meeting

      MOVEMENT DISORDERS
    27. Djaldetti, R; Mosberg-Galili, R; Sroka, H; Merims, D; Melamed, E
      Camptocormia (bent spine) in patients with Parkinson's disease - Characterization and possible pathogenesis of an unusual phenomenon

      MOVEMENT DISORDERS
    28. Giladi, N; Melamed, E
      Levodopa therapy can ameliorate tetrabenazine-induced Parkinsonism

      MOVEMENT DISORDERS
    29. Melamed, E; Olanow, CW; Nutt, JG; Lang, AE
      Dyskinesias Assessment Workshop: Reports from the Working Groups

      MOVEMENT DISORDERS
    30. Offen, D; Gorodin, S; Melamed, E; Hanania, J; Malik, Z
      Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease

      NEUROSCIENCE LETTERS
    31. Melamed, E; Zoldan, J; Galili-Mosberg, R; Ziv, I; Djaldetti, R
      Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa

      JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT
    32. Daily, D; Barzilai, A; Offen, D; Kamsler, A; Melamed, E; Ziv, I
      The involvement of p53 in dopamine-induced apoptosis of cerebellar granuleneurons and leukemic cells overexpressing p53

      CELLULAR AND MOLECULAR NEUROBIOLOGY
    33. Merims, D; Ziv, I; Djaldetti, R; Melamed, E
      Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease

      LANCET
    34. Ziv, I; Melamed, E
      Enhanced fatigue during motor performance in patients with PD - Reply

      NEUROLOGY
    35. Melamed, E; Friedberg, G; Zoldan, J
      Psychosis - Impact on the patient and family

      NEUROLOGY
    36. Offen, D; Mosberg, R; Stern-Goldberg, H; Melamed, E; Halevi, S; Orion, D; Atlas, D
      Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels - Reply

      NEUROLOGY
    37. Gadoth, N; Melamed, E; Miller, A; Steiner, I; Abramsky, O
      Intravenous immunoglobulin treatment in multiple sclerosis

      NEUROLOGY
    38. Shirvan, A; Ziv, I; Fleminger, G; Shina, R; He, ZG; Brudo, I; Melamed, E; Barzilai, A
      Semaphorins as mediators of neuronal apoptosis

      JOURNAL OF NEUROCHEMISTRY
    39. Ziv, I; Avraham, M; Dabby, R; Zoldan, J; Djaldetti, R; Melamed, E
      Early-occurrence of manual motor blocks in Parkinson's disease: a quantitative assessment

      ACTA NEUROLOGICA SCANDINAVICA
    40. ZIV I; MELAMED E
      ROLE OF APOPTOSIS IN THE PATHOGENESIS OF PARKINSONS-DISEASE - A NOVELTHERAPEUTIC OPPORTUNITY

      Movement disorders
    41. DJALDETTI R; ZIV I; MELAMED E
      EXTREME ANTICIPATION IN YOUNG-ONSET PARKINSONS-DISEASE

      Movement disorders
    42. MELAMED E; OFFEN D; SHIRVAN A; DJALDETTI R; BARZILAI A; ZIV I
      LEVODOPA TOXICITY AND APOPTOSIS

      Annals of neurology
    43. SHIRVAN A; ZIV I; ZILKHAFALB R; MACHLYN T; BARZILAI A; MELAMED E
      EXPRESSION OF CELL CYCLE-RELATED GENES DURING NEURONAL APOPTOSIS - ISTHERE A DISTINCT PATTERN

      Neurochemical research
    44. FRIEDBERG G; ZOLDAN J; WEIZMAN A; MELAMED E
      PARKINSON PSYCHOSIS RATING-SCALE - A PRACTICAL INSTRUMENT FOR GRADINGPSYCHOSIS IN PARKINSONS-DISEASE

      Clinical neuropharmacology
    45. ZIV I; DJALDETTI R; ZOLDAN Y; AVRAHAM M; MELAMED E
      DIAGNOSIS OF NONORGANIC LIMB PARESIS BY A NOVEL OBJECTIVE MOTOR-ASSESSMENT - THE QUANTITATIVE HOOVERS TEST

      Journal of neurology
    46. OFFEN D; HALEVI S; ORION D; MOSBERG R; STERNGOLDBERG H; MELAMED E; ATLAS D
      ANTIBODIES FROM ALS PATIENTS INHIBIT DOPAMINE RELEASE MEDIATED BY L-TYPE CALCIUM CHANNELS

      Neurology
    47. DJALDETTI R; MELAMED E
      MANAGEMENT OF RESPONSE FLUCTUATIONS - PRACTICAL GUIDELINES

      Neurology
    48. ZIV I; SHIRVAN A; BARZILAI A; FLEMINGER G; MELAMED E
      PROTECTIVE EFFECT OF ANTI-COLLAPSIN-1 ANTIBODY AGAINST DOPAMINE AND MPP- POSSIBLE IMPLICATIONS FOR NEURODEGENERATIVE DISORDERS( TOXICITY INPOSTMITOTIC NEURONS )

      Neurology
    49. Ziv, I; Avraham, M; Michaelov, Y; Djaldetti, R; Dressler, R; Zoldan, J; Melamed, E
      Enhanced fatigue during motor performance in patients with Parkinson's disease

      NEUROLOGY
    50. OFFEN D; BEART PM; CHEUNG NS; PASCOE CJ; HOCHMAN A; GORODIN S; MELAMED E; BERNARD R; BERNARD O
      TRANSGENIC MICE EXPRESSING HUMAN BCL-2 IN THEIR NEURONS ARE RESISTANTTO 6-HYDROXYDOPAMINE AND 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINENEUROTOXICITY

      Proceedings of the National Academy of Sciences of the United Statesof America
    51. HOCHMAN A; STERNIN H; GORODIN S; KORSMEYER S; ZIV I; MELAMED E; OFFEN D
      ENHANCED OXIDATIVE STRESS AND ALTERED ANTIOXIDANTS IN BRAINS OF BCL-2-DEFICIENT MICE

      Journal of neurochemistry
    52. ZIV I; OFFEN D; HAVIV R; STEIN R; PANET H; ZILKHAFALB R; SHIRVAN A; BARZILAI A; MELAMED E
      THE PROTOONCOGENE BCL-2 INHIBITS CELLULAR TOXICITY OF DOPAMINE - POSSIBLE IMPLICATIONS FOR PARKINSONS-DISEASE

      Apoptosis
    53. SHIRVAN A; BARZILAI A; ZIV I; FLEMINGER G; MACHLIN T; BRUDO I; MELAMED E
      INDUCTION OF COLLAPSIN AND COLLAPSIN RESPONSIVE MEDIATOR IS COUPLED TO NEURONAL APOPTOSIS AND MEDIATE CELL-DEATH

      Molecular biology of the cell
    54. MELAMED LE; MELAMED E
      CASE-STUDY - A LONGITUDINAL EVALUATION OF NEUROPSYCHOLOGICAL FUNCTIONING AND ASSOCIATED BEHAVIORS IN A HIGH-FUNCTIONING AUTISTIC-CHILD

      Archives of clinical neuropsychology
    55. ZIV I; ZILKHAFALB R; OFFEN D; SHIRVAN A; BARZILAI A; MELAMED E
      LEVODOPA INDUCES APOPTOSIS IN CULTURED NEURONAL CELLS - A POSSIBLE ACCELERATOR OF NIGROSTRIATAL DEGENERATION IN PARKINSONS-DISEASE

      Movement disorders
    56. OFFEN D; BEART P; CHOUNG S; PASCOE C; HOCHMAN A; GORODIN S; MELAMED E; BERNARD R; BERNARD O
      TRANSGENIC MICE EXPRESSING HUMAN BCL-2 IN THEIR NEURONS ARE RESISTANTTO NEUROTOXICITY OF 6-OH-DOPAMINE AND MPTP

      Neuroscience letters
    57. ZILKHAFALB R; SHIRVAN A; DJALDETI R; ZIV I; MACHLIN T; MELAMED E; BARZILAI A
      INDUCTION OF T-COMPLEX PROTEIN-1 (TCP-1) EXPRESSION DURING DOPAMINE-TRIGGERED NEURONAL APOPTOSIS IN CHICK-EMBRYO SYMPATHETIC NEURONS

      Neuroscience letters
    58. SHIRVAN A; ZIV I; BARZILAI A; DJALDETI R; ZILKHFALB R; MICHLIN T; MELAMED E
      INDUCTION OF MITOSIS-RELATED GENES DURING DOPAMINE-TRIGGERED APOPTOSIS IN SYMPATHETIC NEURONS

      Journal of neural transmission. Supplementum
    59. ZIV I; BARZILAI A; OFFEN D; NARDI N; MELAMED E
      NIGROSTRIATAL NEURONAL DEATH IN PARKINSONS-DISEASE - A PASSIVE OR AN ACTIVE GENETICALLY-CONTROLLED PROCESS

      Journal of neural transmission. Supplementum
    60. ZIV I; OFFEN D; BARZILAI A; HAVIV R; STEIN R; ZILKHAFALB R; SHIRVAN A; MELAMED E
      MODULATION OF CONTROL MECHANISMS OF DOPAMINE-INDUCED APOPTOSIS - A FUTURE APPROACH TO THE TREATMENT OF PARKINSONS-DISEASE

      Journal of neural transmission. Supplementum
    61. OFFEN D; ZIV I; PANET H; WASSERMAN L; STEIN R; MELAMED E; BARZILAI A
      DOPAMINE-INDUCED APOPTOSIS IS INHIBITED IN PC12 CELLS EXPRESSING BCL-2

      Cellular and molecular neurobiology
    62. ZILKHAFALB R; ZIV I; NARDI N; OFFEN D; MELAMED E; BARZILAI A
      MONOAMINE-INDUCED APOPTOTIC NEURONAL CELL-DEATH

      Cellular and molecular neurobiology
    63. OFFEN D; ZIV I; BARZILAI A; GORODIN S; GLATER E; HOCHMAN A; MELAMED E
      DOPAMINE-MELANIN INDUCES APOPTOSIS IN PC12 CELLS - POSSIBLE IMPLICATIONS FOR THE ETIOLOGY OF PARKINSONS-DISEASE

      Neurochemistry international
    64. SHANKMAN S; BELTRAN J; MELAMED E; ROSENBERG ZS
      ANTERIOR HORN OF THE LATERAL MENISCUS - ANOTHER POTENTIAL PITFALL IN MR-IMAGING OF THE KNEEL

      Radiology
    65. DJALDETTI R; ROSMARIN V; ZIV I; MELAMED E
      THE PHARMACOKINETIC PROFILE OF THE FIRST EVER ORAL DOSE OF LEVODOPA IN DE-NOVO PATIENTS WITH PARKINSONS-DISEASE

      Neurology
    66. ZIV I; SHIRVAN A; BARZILAI A; DJALDETTI R; MELAMED E
      NEURONAL APOPTOSIS TRIGGERED BY DOPAMINE IS ASSOCIATED WITH INDUCTIONOF THE COLLAPSIN SYSTEM

      Neurology
    67. SHIRVAN A; ZIV I; MACHLIN T; ZILKHAFALB R; MELAMED E; BARZILAI A
      2 WAVES OF CYCLIN-B AND PROLIFERATING CELL NUCLEAR ANTIGEN EXPRESSIONDURING DOPAMINE-TRIGGERED NEURONAL APOPTOSIS

      Journal of neurochemistry
    68. DJALDETTI R; ACHIRON A; ZIV I; DJALDETTI M; MELAMED E; FISHMAN P
      IL-3-LA PRODUCTION BY MONONUCLEAR-CELLS OF PATIENTS WITH MULTIPLE-SCLEROSIS - EFFECT OF TREATMENT WITH INTRAVENOUS IMMUNOGLOBULINS (VOL 24,PG 765, 1995)

      Immunological investigations
    69. DJALDETTI R; MELAMED E
      LEVODOPA ETHYLESTER - A NOVEL RESCUE THERAPY FOR RESPONSE FLUCTUATIONS IN PARKINSONS-DISEASE

      Annals of neurology
    70. DJALDETTI R; ATLAS D; MELAMED E
      EFFECT OF SUBCUTANEOUS ADMINISTRATION OF LEVODOPA ETHYL-ESTER, A SOLUBLE PRODRUG OF LEVODOPA, ON DOPAMINE METABOLISM IN RODENT STRIATUM - IMPLICATION FOR TREATMENT OF PARKINSONS-DISEASE

      Clinical neuropharmacology
    71. DJALDETTI R; BARON J; ZIV I; MELAMED E
      GASTRIC-EMPTYING IN PARKINSONS-DISEASE - PATIENTS WITH AND WITHOUT RESPONSE FLUCTUATIONS

      Neurology
    72. DJALDETTI R; ZIV I; ACHIRON A; MELAMED E
      FATIGUE IN MULTIPLE-SCLEROSIS COMPARED WITH CHRONIC FATIGUE SYNDROME - A QUANTITATIVE ASSESSMENT

      Neurology
    73. ZIV I; SHIRVAN A; DJALDETTI R; MICHLIN T; BARZILAI A; MELAMED E
      NEURONAL APOPTOSIS INDUCED BY DOPAMINE IS ASSOCIATED WITH CELL CYCLE-RELATED EVENTS - CLUES FOR NIGRAL DEGENERATION IN PARKINSONS-DISEASE

      Neurology
    74. DJALDETTI R; ZIV I; MELAMED E
      IMPAIRED ABSORPTION OF ORAL LEVODOPA - A MAJOR CAUSE FOR RESPONSE FLUCTUATIONS IN PARKINSONS-DISEASE

      Israel journal of medical sciences
    75. OFFEN D; ZIV I; STERNIN H; MELAMED E; HOCHMAN A
      PREVENTION OF DOPAMINE-INDUCED CELL-DEATH BY THIOL ANTIOXIDANTS - POSSIBLE IMPLICATIONS FOR TREATMENT OF PARKINSONS-DISEASE

      Experimental neurology
    76. DJALDETTI R; MELAMED E
      POSTRAUMATIC-DELAYED CEREBELLAR SYNDROME

      Archives of neurology
    77. YAMASHITA M; ACHIRON A; MIURA T; TAKEHISA J; IDO E; IGARASHI T; IBUKI K; OSAME M; SONODA S; MELAMED E; HAYAMI M; SHOHAT B
      HTLV-I FROM IRANIAN-MASHHADI JEWS IN ISRAEL IS PHYLOGENETICALLY RELATED TO THAT OF JAPAN, INDIA, AND SOUTH-AMERICA RATHER THAN TO THAT OF AFRICA AND MELANESIA

      Virus genes
    78. DJALDETTI R; KOREN M; ZIV I; ACHIRON A; MELAMED E
      EFFECT OF CISAPRIDE ON RESPONSE FLUCTUATIONS IN PARKINSONS-DISEASE

      Movement disorders
    79. DJALDETTI R; ACHIRON A; ZIV I; DJALDETTI M; MELAMED E; FISHMAN P
      IL-3-LA PRODUCTION BY MONONUCLEAR-CELLS OF PATIENTS WITH MULTIPLE-SCLEROSIS - EFFECT OF TREATMENT WITH INTRAVENOUS IMMUNOGLOBULINS

      Immunological investigations
    80. YOUDIM MBH; MELAMED E; RECHES A; TATTON W; COMMISSIONG J; LAVY R; FINBERG JPM
      NEUROPROTECTIVE AND NEURORESCUE ACTIVITIES OF RASAGILINE (TVP 1012,N-PROPARGYL-1 [R]-AMINO-INDAN)

      Annals of neurology
    81. OFFEN D; ZIV I; STEIN R; HOCHMAN A; SHIRVAN A; PANET H; GORDIN S; BARZILAI A; MELAMED E
      CELLULAR PROTECTIVE EFFECT OF BCL-2 AGAINST DOPAMINE-INDUCED APOPTOSIS - AN ASSOCIATION WITH ANTIOXIDANT PATHWAYS

      Annals of neurology
    82. DJALDETTI R; ATLAS D; MELAMED E
      LEVODOPA ETHYLESTER - A NOVEL THERAPEUTIC STRATEGY FOR TREATMENT OF RESPONSE FLUCTUATIONS IN PATIENTS WITH PARKINSONS-DISEASE

      Annals of neurology
    83. MELAMED E
      DOES TREATMENT WITH DOPAMINE AGONISTS AFFECT UTILIZATION OF EXOGENOUSLEVODOPA IN THE PARKINSONIAN STRIATUM

      Journal of neural transmission. Supplementum
    84. OFFEN D; ZIV I; GORODIN S; BARZILAI A; MALIK Z; MELAMED E
      DOPAMINE-INDUCED PROGRAMMED CELL-DEATH IN MOUSE THYMOCYTES

      Biochimica et biophysica acta. Molecular cell research
    85. NERURKAR VR; ACHIRON A; SONG KJ; MELLAND RR; PINHASHAMIEL O; MELAMED E; SHOHAT B; YANAGIHARA R
      HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I IN IRANIAN-BORN MASHHADI JEWS - GENETIC AND PHYLOGENETIC EVIDENCE FOR COMMON SOURCE OF INFECTION

      Journal of medical virology
    86. ZOLDAN J; FRIEDBERG C; LIVNEH M; MELAMED E
      PSYCHOSIS IN ADVANCED PARKINSONS-DISEASE - TREATMENT WITH ONDANSETRON, A 5-HT3 RECEPTOR ANTAGONIST

      Neurology
    87. ZOLDAN J; FRIEDBERG G; WEIZMAN A; MELAMED E
      PSYCHOSIS IN LEVODOPA-TREATED PARKINSONIAN-PATIENTS - CLINICAL-FEATURES AND RESPONSE TO ONDANSETRON, A SELECTIVE 5-HT3 ANTAGONIST

      Neurology
    88. GOLDBERGSTERN H; NAVON R; SEIFRIED B; SADEH M; MEER J; GABAY U; MELAMED E; GADOTH N
      CHARCOT-MARIE-TOOTH (CMT) DISEASE IN ISRAEL - CLINICAL, EPIDEMIOLOGIC, AND GENETIC-ASPECTS

      Neurology
    89. DJALDETTI R; ATLAS D; MELAMED E
      SUBCUTANEOUS INJECTIONS OF LEVODOPA ETHYLESTER - A POTENTIAL NOVEL RESCUE THERAPY FOR RESPONSE FLUCTUATIONS IN PATIENTS WITH PARKINSONS-DISEASE

      Neurology
    90. ZIV I; OFFEN D; BARZILAY A; STEIN R; MELAMED E
      THE PROTOONCOGENE BCL-2, A NOVEL CELLULAR PROTECTIVE MECHANISM AGAINST DOPAMINE TOXICITY - POSSIBLE IMPLICATIONS FOR PARKINSONS-DISEASE

      Neurology
    91. ACHIRON A; COHEN IR; LIDER O; MELAMED E
      INTRAVENOUS IMMUNOGLOBULIN TREATMENT IN MULTIPLE-SCLEROSIS

      Israel journal of medical sciences
    92. HERING R; ACHIRON A; MELAMED E
      LEFT-HANDEDNESS AND MULTIPLE-SCLEROSIS

      Neuropsychiatry, neuropsychology, and behavioral neurology
    93. DJALDETTI R; ACHIRON A; ZIV I; MELAMED E
      FIRST EMERGENCE OF DELAYED-ON AND DOSE FAILURE PHENOMENA IN A PATIENTWITH PARKINSONS-DISEASE FOLLOWING VAGOTOMY

      Movement disorders
    94. ZIV I; ACHIRON A; DJALDETTI R; ABRAHAM M; MELAMED E
      CAN NIMODIPINE AFFECT PROGRESSION OF MOTOR-NEURON DISEASE - A DOUBLE-BLIND PILOT-STUDY

      Clinical neuropharmacology
    95. ZIV I; MELAMED E; NARDI N; LURIA D; ACHIRON A; OFFEN D; BARZILAI A
      DOPAMINE INDUCES APOPTOSIS-LIKE CELL-DEATH IN CULTURED CHICK SYMPATHETIC NEURONS - A POSSIBLE NOVEL PATHOGENETIC MECHANISM IN PARKINSONS-DISEASE

      Neuroscience letters
    96. GOLDBERGSTERN H; DJALDETTI R; MELAMED E; GADOTH N
      MACHADO-JOSEPH (AZOREAN)-DISEASE IN A YEMENITE JEWISH FAMILY IN ISRAEL

      Neurology
    97. ZIV I; BARZILAY A; NARDI N; ACHIRON A; OFFEN D; MELAMED E
      DOPAMINE INDUCES APOPTOSIS-LIKE CELL-DEATH IN CULTURED SYMPATHETIC NEURONS - A POSSIBLE NOVEL PATHOGENETIC MECHANISM IN PARKINSONS-DISEASE

      Neurology
    98. DJALDETTI R; ACHIRON A; ZIV I; DABBY R; MOSBERG R; MELAMED E
      THE EFFECT OF SINEMET TABLETS VERSUS SUSPENSION OF CRUSHED SINEMET ONDELAYED-ON AND NO-ON FLUCTUATIONS IN PARKINSONS-DISEASE

      Neurology
    99. ACHIRON A; PINHASHAMIEL O; DOLL L; SHOHAT B; CHEN A; DJALDETTI R; ZIV I; MELAMED E; FRANKEL G
      HTLV-1-ASSOCIATED CHRONIC PROGRESSIVE MYELOPATHY IN IRANIAN-BORN JEWS- IMPLICATIONS FOR HORIZONTAL TRANSMISSION BY DETECTION OF PROVIRAL GENOME IN SALIVA

      Neurology
    100. ZOLDAN J; FRIEDBERG G; WEIZMAN A; MELAMED E; TIQVA P
      ZOFRAN (ONDANSETRON), A 5-HT3 RECEPTOR ANTAGONIST - ADMINISTRATION IN16 PATIENTS WITH PARKINSONS-DISEASE AND LEVODOPA-ASSOCIATED PSYCHOSIS

      Neurology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/10/20 alle ore 08:50:14